Minireviews
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 14, 2021; 27(26): 4182-4193
Published online Jul 14, 2021. doi: 10.3748/wjg.v27.i26.4182
Prevention of vertical transmission of hepatitis B virus infection
Piero Veronese, Icilio Dodi, Susanna Esposito, Giuseppe Indolfi
Piero Veronese, Susanna Esposito, Department of Medicine and Surgery, University of Parma, Parma 43121, Italy
Icilio Dodi, Department of Pediatrics, Pietro Barilla Children's Hospital, Parma 43121, Italy
Giuseppe Indolfi, Department Neurofarba, University of Florence, Florence 50129, Italy
Giuseppe Indolfi, Department Neurofarba, Meyer Children's University Hospital, Florence 50129, Italy
Author contributions: Veronese P and Indolfi G wrote the paper; Dodi I and Esposito S revised it critically for significant intellectual content.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Giuseppe Indolfi, MD, Professor, Department Neurofarba, University of Florence, Viale Gaetano Pieraccini, 24, Florence 50129, Italy. giuseppe.indolfi@meyer.it
Received: February 5, 2021
Peer-review started: February 5, 2021
First decision: March 14, 2021
Revised: March 29, 2021
Accepted: June 2, 2021
Article in press: June 2, 2021
Published online: July 14, 2021
Processing time: 156 Days and 3.3 Hours
Abstract

Hepatitis B virus (HBV) is the leading cause of chronic viral hepatitis. Annually, almost two million children younger than 5 years acquire the infection, mostly through vertical or horizontal transmission in early life. Vertical transmission of HBV is a high efficacy phenomenon ranging, in the absence of any preventive interventions, from 70% to 90% for hepatitis e antigen positive mothers and from 10% to 40% for hepatitis e antigen-negative mothers. Maternal viraemia is a preeminent risk factor for vertical transmission of HBV. Maternal screening is the first step to prevent vertical transmission of HBV. Hepatitis B passive and active immunoprophylaxis at birth together with antiviral treatment of highly viraemic mothers are the key strategies for global elimination of HBV infection. Strategies are needed to promote implementation of birth-dose vaccination and hepatitis B immunoglobulins in low- and middle-income countries where the prevalence of the infection is at the highest.

Keywords: Hepatitis B; Vertical transmission; Hepatitis B vaccine; Hepatitis B immune globulin; Neonatal immunoprophylaxis; Tenofovir alafenamide fumarate

Core Tip: Hepatitis B is one of the main causes of morbidity and mortality worldwide. Vertical transmission is the main transmission route, especially in areas with high prevalence of the infection. Maternal viraemia is a preeminent risk factor for vertical transmission of hepatitis B virus (HBV). Breastfeeding is recommended, although all the conditions leading to maternal-foetal microtransfusions with HBV-infected maternal blood increase the risk of vertical transmission. Neonatal immunoprophylaxis at birth represent the most important approach to prevent HBV infection. The aim of the present narrative review is to summarise the knowledge on prevention of vertical transmission of HBV infection.